In today’s briefing:
- China Healthcare Weekly (Dec.29) – Haier Biomedical Plans to Merge with and Absorb Shanghai RAAS
- Penumbra Inc.: An Insight Into Its Margin Expansion Opportunities & Other Major Drivers
China Healthcare Weekly (Dec.29) – Haier Biomedical Plans to Merge with and Absorb Shanghai RAAS
- Haier Biomedical plans to merge with and absorb Shanghai RAAS through the issuance of shares, and both parties have signed a letter of intent for the potential merger.
- Haier’s acquisition of RAAS helps connect the software and hardware of the blood industry and strengthen the company’s dominant position in the entire industry chain in the blood products industry.
- The market value/financial performance of these two are far apart. If the acquisition is completed, it will help Haier improve financial performance, which is obviously more beneficial for Haier.
Penumbra Inc.: An Insight Into Its Margin Expansion Opportunities & Other Major Drivers
- Penumbra reported a solid performance in its third quarter of 2024, with total revenue of $301 million, marking an 11.1% increase year-over-year on a reported basis, and 10.9% in constant currency.
- The results show robust growth in the U.S. thrombectomy business, which rose by 21.2% year-over-year, driven significantly by advancements in their catheter technology, particularly with the Lightning Flash 2.0 and Lightning Bolt 7 products.
- Despite this robust growth in the U.S., the company faced challenges internationally, with revenues decreasing slightly by 1.9% reported due to a notable reduction in sales within China.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
